Health
Health is a sector shaped both by global trends, technologies and innovation, and by local market conditions, demographics and regulations.
Investment and consolidation in Asia are driven by:
- The growth in disposable income, rapidly changing and diversely different demographics;
- Geographically and physiologically distinct characteristics;
- The evolution of government-sponsored health systems; and
- The emergence of true innovators in medical and life science technologies within the region
- Access to these growth markets by global participants, and the thirst of regional actors for M&A in both directions between Asia and the West.
Our global Health team serves our corporate, financial sponsor and entrepreneurial clients by combining our deep local capability and insights across Asia with our global perspectives and transactional track record. Our experience spans healthcare services, medical technology, pharma and biotech, outsourced pharma services (CRO, CDMO), consumer health, and animal & plant life sciences.
Andrew Huntley
Managing Partner, Head of Healthcare
Sanjay Singh
Partner, Head of Mumbai, Head of Healthcare, Asia
Sophia Wu
Managing Director, Head of Healthcare, China
divested majority stake in
to
2024
acquired majority stake in
2024
has been acquired by
2023
received investment from
2023
a subsidiary of
has acquired
2022
a portfolio company of
has been acquired by
2022
agreed to divest East Syracuse, New York facility to
2022
has sold minority stake to
2022
a portfolio company of
has been acquired by
2022
investment from
2021
has been acquired by
2021
a portfolio company of
has been acquired majority stake by
2021
a portfolio company of
has been acquired by
2021
divested majority stake to
DCP Capital
2021
agreed to divest Couvet, Switzerland facility to WuXi AppTec
2021
raised Series B round from
2021
backed by
has been acquired by
2020
divested Escientia Life Sciences to Deccan Fine Chemicals
2020
divested significant stake in
Kehua Bio-Engineering to Gree Real Estate
2020
majority sale
2019
LAP Lasers a portfolio company of
has been acquired by
2019
divested majority stake to
2019
a portfolio company of
has been acquired by
AGIC and Humanwell
2017
recapitalized majority by
2017
divested CMC Biologics to
2017
has been acquired by a Japanese chemicals & life science company
2016
acquired Adval Tech Medical (Suzhou) and Omni Manufacturing (Mexico)
2013
divested Radiant Research Inc, US-based clinical research company
2012
divested medical supply business to
2012
established an animal vaccine JV with Jilin Guoyuan Animal Health
2011